Keros Therapeutics, Inc. (KROS)
NASDAQ: KROS · IEX Real-Time Price · USD
58.95
-0.32 (-0.54%)
At close: Apr 18, 2024, 4:00 PM
56.01
-2.94 (-4.99%)
After-hours: Apr 18, 2024, 7:07 PM EDT
Keros Therapeutics Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for Keros Therapeutics stock have an average target of 86, with a low estimate of 60 and a high estimate of 105. The average target predicts an increase of 45.89% from the current stock price of 58.95.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for KROS stock from 6 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 3 | 4 | 4 | 4 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 7 | 7 | 7 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Buy Maintains $105 | Buy | Maintains | $105 | +78.12% | Mar 27, 2024 |
| Truist Securities | Truist Securities | Strong Buy Reiterates $100 | Strong Buy | Reiterates | $100 | +69.64% | Mar 13, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $100 | Strong Buy | Reiterates | $100 | +69.64% | Mar 1, 2024 |
| Wells Fargo | Wells Fargo | Buy Initiates $60 | Buy | Initiates | $60 | +1.78% | Dec 8, 2023 |
| Wedbush | Wedbush | Buy Reiterates $86 | Buy | Reiterates | $86 | +45.89% | Nov 13, 2023 |
Financial Forecast
Revenue This Year
6.43M
from 151.00K
Increased by 4,155.63%
Revenue Next Year
22.66K
from 6.43M
Decreased by -99.65%
EPS This Year
-5.38
from -5.20
EPS Next Year
-5.58
from -5.38
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 31.5M | 210,000 | 136.7M | 408.3M | 870.3M |
| Avg | 6.4M | 22,664 | 25.4M | 181.5M | 463.7M |
| Low | n/a | n/a | n/a | n/a | 63.7M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 20,760.9% | -96.7% | 602,872.1% | 1,507.2% | 379.4% |
| Avg | 4,155.6% | -99.6% | 111,992.1% | 614.6% | 155.4% |
| Low | - | - | - | - | -64.9% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -4.63 | -3.91 | -4.06 | 2.04 | 7.89 |
| Avg | -5.38 | -5.58 | -5.50 | -3.51 | 0.40 |
| Low | -6.17 | -6.84 | -7.05 | -6.76 | -6.27 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.